Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com
Prostate Cancer

Personalized prostate cancer care starts with genomic testing

Active surveillance. Surgery. Radiation. Hormonal therapies. When it comes to prostate cancer, there’s a whole arsenal of management and treatment options. But which one is right for you? Which regimen will fight hardest against your particular prostate cancer?

 

With the help of insights from the advanced genomics of the Oncotype DX® prostate cancer tests, you and your doctor can make informed treatment decisions based on the individual characteristics of your unique tumor.

Less Aggressive vs More Aggressive Treatment

Oncotype DX GPS

Oncotype DX Genomic Prostate Score® (GPSTM) test

For patients with both low-risk and high-risk localized prostate cancer

Learn about the genomic test that can help predict how aggressive your localized, early stage prostate cancer is, and the likelihood of it spreading (metastasizing) within 10 years of surgery. Plus, get an understanding of the testing process, learn what you can expect from the test results, watch patient stories, explore FAQs, and more.

Do you know your GPS result? Meet Jim and hear how he used his GPS results to choose active surveillance as his treatment strategy.

Oncotype DX AR-V7 Nucleus Detect

Oncotype DX AR-V7 Nucleus Detect® test

For patients with late-stage metastatic castration-resistant prostate cancer (mCRPC)

The AR-V7 Nucleus Detect® test gives you important insights into your late-stage metastatic castration-resistant prostate cancer (mCRPC) to help you and your doctor quickly and confidently decide on the next steps in your treatment. Plus, get an understanding of the testing process, learn what you can expect from the test results, explore FAQs, and more.

Most patients pay $0 to minimal out-of-pocket costs*
Learn about costs, coverage, and how Exact Sciences can help

 


*This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your patient’s insurer can confirm if and how the Oncotype DX test will be covered.